Table.

Baseline characteristics, arrhythmia burden, clinical management, acute and intermediate outcomes are shown for patients in the study.

Patient	Age/Gender	Substrate/ LV EF	VT Type	Anti-arrhythmics	GA /TEA	VT RFA	Arrhythmia Episodes / Arrhythmia Therapies* Pre-BCSD	Arrhythmia Episodes / Arrhythmia Therapies* Post BCSD	Response to BCSD	Survival to Discharge	intermediate Follow up (Days post- Discharge)
1	69 / M	Sarcoid / 20%	MMVT	Carvedilol Amiodarone	No / No	2 Endo	45 / 30 (14 Days)	3 / 2 (6 Days)	Partial	Yes	Death CHF (89 Days)
2	66 / F	NICM / 20%	PMVT	Amiodarone Lidocaine Metoprolol	Yes / Yes	n/a	51 / 6 (13 Days)	27 / 2 (8 Days)	Poor	No	n/a
3	55 / M	NICM / 20%	MMVT	Amiodarone Carvedillol Lidocaine, Mexiletine	No / No	2 Endo 1 Epi	39 / 17 (9 Days)	0 / 0 (3 Days)	Complete	Yes	Alive (207 Days)
4	47 / M	NICM / 15%	MMVT	Amiodarone Esmolol Diltiazem Carvedilol Verapamil Lidocaine Procainamide	Yes / Yes	3 Endo	87 / 11 (28 Days)	0 / 0 (7 Days)	Complete	Yes	Alive (153 Days)
5	49 / M	NICM / 40%	MMVT	Amiodarone metoprolol	No / No	2 Endo	43 / 25 (15 Days)	0 / 0 (14 Days)	Complete	Yes	Alive (129 Days)
6	75 / M	ARVC / 40%	MMVT	Amiodarone Metoprolol	No / No	2 Endo 1 Epi	36 / 36 (14 Days)	0 / 0 (14 Days)	Complete	Yes	Death Unknown Cause (21 Days)

^*Therapies: Automated or Manual Defibrillation, and Anti-Tachycardia pacing.

ARVC – Arrhythmogenic Right Ventricular Cardiomyopathy, BCSD – Bilateral Cardiac Sympathetic Denervation, CHF – Congestive Heart Failure, Endo – Endocardial, Epi –Epicardial, GA – General Anesthesia, Ventricular Ejection Fraction, VT – Ventricular Tachycardia, NICM – Non-Ischemic Cardiomyopathy, TEA – Thoracic Epidural Anesthesia, MMVT – Monomorphic Ventricular tachycardia, PMVT –Polymorphic Therapies: Automated or Manual Defibrillation, and Anti-Tachycardia pacing. Anesthesia, M – Male, F – Female, LV EF – Left tachycardia, PMVT – Polymorphic Ventricular Tachycardia